말레이시아 - 영어 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

말레이시아 - 영어 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

말레이시아 - 영어 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - cabozantinib (s)-malate -

캐나다 - 영어 - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 20mg - cabozantinib (cabozantinib malate) 20mg - antineoplastic agents

캐나다 - 영어 - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 40mg - cabozantinib (cabozantinib malate) 40mg - antineoplastic agents

캐나다 - 영어 - Health Canada

ipsen biopharmaceuticals canada inc - cabozantinib (cabozantinib malate) - tablet - 60mg - cabozantinib (cabozantinib malate) 60mg - antineoplastic agents

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - cabozantinib (s)-malate, quantity: 50.69 mg (equivalent: cabozantinib, qty 40 mg) - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; hypromellose; croscarmellose sodium; iron oxide yellow; hyprolose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; triacetin - renal cell carcinoma (rcc),cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):,- in treatment-na?ve adults with intermediate or poor risk,- in adults following prior treatment with vascular endothelial growth factor targeted therapy.,cabometyx in combination with nivolumab is indicated for the first-line treatment of advanced renal cell carcinoma.,hepatocellular carcinoma (hcc),cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.,differentiated thyroid carcinoma (dtc),cabometyx is indicated as monotherapy for the treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (dtc) that has progressed during or after prior vegfr-targeted therapy and who are radioactive iodine (rai) refractory or ineligible.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - cabozantinib (s)-malate, quantity: 25.34 mg (equivalent: cabozantinib, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; triacetin; titanium dioxide; lactose; microcrystalline cellulose; colloidal anhydrous silica; hyprolose; croscarmellose sodium; hypromellose; iron oxide yellow - renal cell carcinoma (rcc),cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):,- in treatment-na?ve adults with intermediate or poor risk,- in adults following prior treatment with vascular endothelial growth factor targeted therapy.,cabometyx in combination with nivolumab is indicated for the first-line treatment of advanced renal cell carcinoma.,hepatocellular carcinoma (hcc),cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.,differentiated thyroid carcinoma (dtc),cabometyx is indicated as monotherapy for the treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (dtc) that has progressed during or after prior vegfr-targeted therapy and who are radioactive iodine (rai) refractory or ineligible.

이스라엘 - 영어 - Ministry of Health

medison pharma ltd - cabozantinib as (s) malate - film coated tablets - cabozantinib as (s) malate 20 mg - cabozantinib - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for advanced renal cell carcinoma- as first-line treatment of adult patients with intermediate or poor risk, per imdc criteria.- in adults following prior vascular endothelial growth factor (vegf)-targeted therapy.cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc), in adults with child-pugh class a hepatic impairment who have previously been treated with sorafenib.differentiated thyroid carcinoma (dtc)cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (dtc), refractory or not eligible to radioactive iodine (rai) who have progressed during or after prior systemic therapy.